COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 3.49 CAD -2.51% Market Closed
Market Cap: 11.3m CAD

COSCIENS Biopharma Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

COSCIENS Biopharma Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
COSCIENS Biopharma Inc
TSX:CSCI
EPS (Diluted)
-$5
CAGR 3-Years
-40%
CAGR 5-Years
-69%
CAGR 10-Years
39%
B
Bright Minds Biosciences Inc
CNSX:DRUG
EPS (Diluted)
CA$0
CAGR 3-Years
49%
CAGR 5-Years
-130%
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
EPS (Diluted)
$0
CAGR 3-Years
29%
CAGR 5-Years
5%
CAGR 10-Years
-5%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
EPS (Diluted)
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
EPS (Diluted)
-$3
CAGR 3-Years
-39%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
EPS (Diluted)
CA$0
CAGR 3-Years
-26%
CAGR 5-Years
-10%
CAGR 10-Years
-7%

COSCIENS Biopharma Inc
Glance View

Market Cap
11m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
13.2 CAD
Undervaluation 74%
Intrinsic Value
Price

See Also

What is COSCIENS Biopharma Inc's EPS (Diluted)?
EPS (Diluted)
-5.6 USD

Based on the financial report for Mar 31, 2025, COSCIENS Biopharma Inc's EPS (Diluted) amounts to -5.6 USD.

What is COSCIENS Biopharma Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
39%

Over the last year, the EPS (Diluted) growth was 13%. The average annual EPS (Diluted) growth rates for COSCIENS Biopharma Inc have been -40% over the past three years , -69% over the past five years , and 39% over the past ten years .

Back to Top